SUBJECT INDEX

A

Acetaldehyde
  sister chromatid exchange and, 232
Acetaminophen
  hepatotoxicity/nephrotoxicity of, 23
  hepatotoxicity of, 181-83
    glutathione depletion and, 607-8
  peroxidase-dependent oxidation of, 14
  prostaglandin H synthase activity and, 7
cis-Acetoxy-S-methylthiane
  muscarinic receptors and, 634
2-Acetylaminofluorene
  altered hepatic foci and, 466
  forestomach tumors and, 446
  procarcinogenicity of, 169
Acetylbenzidine
  mutagenicity of, 19
  prostaglandin H synthase peroxidase and, 16
Acetylcholine
  lymphocyte receptors for, 582-83
  phencyclidine and, 714
Acetylcholinesterase
  organophosphorus-induced delayed neurotoxicity and, 428-29
  paraoxon and, 171
N-Acetylcysteine
  galactosamine-induced hepatic necrosis and, 301
  S-nitroso derivatives of, 540
N-Acetyl-*p*-benzoquinone imine
  acetaminophen toxicity and, 182
Acetylsalicyclic acid
  butylated hydroxyanisole-induced cellular proliferation and, 453
Acid phosphatase
  organophosphorus-induced delayed neurotoxicity and, 430
Acro-osteolysis
  trichloroethylene and, 73-74
Acrylamide
  target-organ selectivity of, 176
Actin
  S-thiolation reactions and, 174
Activase
  See Tissue plasminogen activator
Adenocarcinoma
  lung
    trichloroethylene-induced, 84
Adenoma
  growth hormone-secreting
    G proteins and, 695
  lung
    trichloroethylene-induced, 84
Adenylate cyclase
  opioid receptors and, 138-40
Adenylyl cyclase
  G proteins and, 676, 685-86
  serotonin receptors and, 318-19
β-Adrenergic receptor kinase
  muscarinic receptors and, 653-54
Adrenergic receptors
  adenylate cyclase activity and, 138-39
Adrenocorticotropic hormone
  immune responses and, 573-74
Adriamycin
  cytotoxicity of, 181
  1-electron reduction of
    lipid peroxidation and, 180
AF-DX 116
  muscarinic receptors and, 634
Aflatoxin
  in alcoholic beverages, 220
  hydroperoxide-dependent oxidation of, 10
Aflatoxin B1
  carcinogenicity of, 23-24
Aging
  N-methyl-D-aspartate receptors and, 65
β-N-methylamino-L-Alanine
  amyotrophic lateral sclerosis/parkinsonism/dementia complex due to, 53-54
β-N-oxalylamino-L-Alanine
  neurolathyrism due to, 53
Alcohol
  cancer and, 219-35
  as cocarcinogen, 222-33
  cytotoxic and mitogenic effects of, 225-27
  DNA-alkylation repair and, 231-32
  electrophile detoxification and, 230-31
  hepatitis B virus infection and, 233-34
  immunosuppression and, 232-33
  lipid peroxidation and, 230
  microsomal enzyme induction and, 227-29
  nutritional deficiency and, 234-35
  retinol metabolism and, 229-30
  sister chromatid exchange and, 232
Alcoholic beverages
  carcinogens in, 220-22
Alcoholism
  neuronal degeneration due to, 60-61
Aldehydes
  4-hydroxyunsaturated
    cytotoxicity of, 180
Alkylperoxides
  oxidation of
    prostaglandin H synthase peroxidase and, 9
Allyl alcohol
  cytotoxicity of, 176
Allylisothiocyanate
  glutathione conjugates of
    cytotoxicity of, 172
  interorgan translocation of, 173
Alpha-hexachlorocyclohexane
  lesion reversibility and, 455
Altered hepatic foci
  hepatocarcinogenesis and, 465-88
  hepatocellular carcinoma and, 485-87
  histochemistry of, 469
  induction of, 473-77
  morphology of, 466-69
  natural history of, 477-85
  quantitation of, 469-73
Aluminum
  toxicity of
    meso-dimercaptosuccinic acid and, 292-93
Alzheimer's disease
  excitotoxins and, 59-60
Amanita phalloides
  hepatotoxins of, 170
Ames test, 152-53

α-Aminitin
  cellular effects of, 170
Amino acids
  excitotoxic
    cell death due to, 50-51
    central nervous system trauma and, 56-57
    food, 52-54
    metabolic disorders due to, 54-55
    neurodegenerative disorders and, 52-61
    neuropsychiatric disorders and, 47-66
    receptors for, 48-50
  mimicking neurotoxicity of glutamate, 49
Aminoazo dyes
  procarcinogenicity of, 169
4-Aminobiphenol
  binding to macromolecules, 18
2-Aminofluorene
  oxidation of, 18
  prostaglandin H synthase peroxidase and, 16
Aminopyrine
  prostaglandin H synthase peroxidase and, 9, 14, 16-17
Amitrole
  carcinogenicity of, 29
Amnesia
  vasopressin and, 520-21
Amyotrophic lateral sclerosis
  glutamic dehydrogenase and, 55
  β-N-methylamino-L-alanine and, 53-54
Androgens
  α-globulin synthesis and, 352
Aneuploidy
  tumorigenesis and, 161-62
Angiosarcoma
  liver
    vinyl chloride-induced, 74-75
Antibodies
  opioid receptors and, 132-34
Anti-excitotoxic drugs, 48-50
Antiinflammatory drugs
  nonsteroidal
    prostaglandin H synthase cyclooxygenase and, 6
    renal cellular damage due to, 179
Antiplasmin
  tissue plasminogen activator and, 97
Apiol
  delayed neurotoxicity due to, 421
Aprotinin
  tissue plasminogen activator and, 97
Arachidonic acid
  conversion into biologically active metabolites, 2
  metabolism of
    cooxidation of chemicals during, 2
    corticosteroids and, 6-7
  release from membranes
    agents stimulating, 6
Arecaidine
  muscarinic receptors and, 634
Arecoline
  muscarinic receptors and, 634
Arginine
  tissue plasminogen activator and, 96
L-Argininosuccinic acid
  endothelium-dependent relaxation and, 547
Aromatic amines
  carcinogenicity of, 16-21
  cooxidation of, 14
  DNA adducts of, 20
  metabolism of, 16-18
  in vivo activation of, 20-21
Aromatic nitro compounds
  forestomach tumors and, 446
Arsenic
  poisoning with
    meso-dimercaptosuccinic acid and, 289-90, 293-94
Aryl hydrocarbon hydroxylase
  induction of, 253-55, 263
Aryl phosphites
  clinical signs due to, 412-13
Asbestos fibers
  in alcoholic beverages, 220
Aspartate
  neurotoxicity of, 47
N-methyl-D-Aspartate
  excitotoxin receptors sensitive to, 48-50
N-methyl-D-Aspartate receptors
  aging and, 65
  developing central nervous system and, 61-64
  features of, 50-51
  memory and, 64-65
Aspirin
  prostaglandin H synthase and, 4
  in vivo teratogenicity of phenytoin and, 27
ATP
  intracellular
    hydrogen peroxide and, 174
ATPase
  altered hepatic foci and, 469
ATP synthase
  oxidizing agents and, 174
Atropine sulfate
  organophosphorus poisoning and, 428
Autonomic nervous system
  interactions with immune system, 576-87
Avoidance behavior
  vasopressin and, 518-20
Azide anion
  nitric oxide generation and, 537
Azoxymethyl-methylnitrosamine
  tumor induction by alcohol and, 224

B

Bacterial mutagenicity testing, 151-53
BCNU
  See 1,3-Bis(2-chloroethyl)-1-nitrosourea
Beer
  consumption of
    cancer and, 221
Benzaldehyde
  forestomach epithelium and, 448
Benzene
  hematopoietic toxicity of, 27
Benzidine
  binding to macromolecules, 18
  carcinogenicity of, 19
  DNA adducts of, 20
  prostaglandin H synthase peroxidase and, 14, 16
Benzo(a)pyrene
  oxidation of, 10-11
Benzodiazepine
  lymphocyte receptors for, 582-83
Benzylisothiocyanate
  glutathione conjugates of
    cytotoxicity of, 172
    interorgan translocation of, 173
Benzyol peroxide
  glutathione and, 606
Bereavement
  depression and, 563
Bipyridyl compounds
  cell injury caused by, 180
1,3-Bis(2-chloroethyl)-1-nitrosourea
  glutathione reductase and, 174
  intracellular glutathione and, 604

Bismuth
encephalopathy due to *meso*-dimercaptosuccinic acid and, 294
(Bi)sulfite
cocarcinogenicity of, 25-26
peroxidase-catalyzed oxidation of, 13
Blood-brain barrier
anti-excitotoxic drugs and, 49-50
Bone marrow micronucleus tests, 157
Bowel cancer
beer consumption and, 221
Bradykinin
arachidonic acid release from membranes and, 6
Brain
damage to
endogenous excitotoxins and, 62-64
injury to
endogenous excitotoxins and, 56-57
interactions with immune system, 561-89
Breast cancer
alcohol consumption and, 219-20
beer consumption and, 221
Bromobenzene
cytotoxicity of, 176
reactive metabolites of
binding of, 172
2-Bromohydroquinone
nephrotoxicity of, 27
p-Bromophenol
binding of, 172
o-Bromotoluene
binding of, 172
Buspirone
serotonin receptor and, 311
Buthionine sulfoximine
glutathione synthesis and, 604
Butylated hydroxyanisole
carcinogenicity of, 451-52
cell proliferation due to, 455
cytotoxicity of, 454
forestomach carcinogenesis and, 441
forestomach tumors and, 447
genotoxicity of, 452
lesion reversibility and, 455-56
metabolism of, 452-54
Butylated hydroxytoluene
toxicity of, 26
t-Butylhydroperoxide
oxidative stress caused by, 174
Butyrylcholinesterase
organophosphorus-induced delayed neurotoxicity and, 429

C

C1-esterase inhibitor
tissue plasminogen activator and, 97
Cadmium
toxicity of
meso-dimercaptosuccinic acid and, 294-95
Calcium
extracellular
oxidative stress and, 612-15
mitochondrial glutathione and, 608-12
Calcium ion channels
opioids and, 141
Calcium ionophores
arachidonic acid release from membranes and, 6
Cancer
alcohol and, 219-35
Carbachol
muscarinic receptors and, 664
Carbohydrate
tissue plasminogen activator function and, 104-5
Carbon tetrachloride
hepatocarcinogenesis and, 473
hepatotoxiciiy of, 180
reactive metabolites of
binding of, 179-80
5-Carboxamidotryptamine
serotonin receptor and, 311
Carcinogenesis
in rodents
short-term tests and, 149-63
Carcinogenicity
chloroethylene, 73-88
Carcinogens
in alcoholic beverages, 220-22
chemical
rodent forestomach and, 445-48
comparative pharmacokinetics and, 209-10
conversion to electrophilic metabolites, 1
nongenotoxic
assays for, 158-62
Carcinoma
hepatocellular
alcohol abuse and, 220
altered hepatic foci and, 485-87
hepatitis B virus and, 233-34
Catecholamines
thymocytes and, 577-78
Catecholamine transporter
xylamine and, 390
Cell death
excitotoxic, 50-51
Cell injury, 169-84
covalent interactions and, 170-73
noncovalent interactions and, 173-75
oxidative stress and, 612-15
protein thiols and, 617
Cell-mediated immunity
pyridoxine and, 236
Central nervous system
damage to
glutamate causing, 48
developing
N-methyl-D-aspartate receptors and, 61-64
neurohypophyseal antagonists and, 522-23
neurohypophyseal hormones and, 516-22
trauma to
endogenous excitotoxins and, 56-57
Cerebral ischemia
endogenous excitotoxins and, 56
Chelation therapy
lead toxicity and, 280
Chemical mutagenesis testing
development of, 150-53
Chemical toxicity
xenobiotic metabolism and, 1
Chloramphenicol
reactive metabolites of
covalent interactions of, 172
Chloroacetaldehyde
mutagenicity of, 75
Chloroethylenes
carcinogenicity of, 73-88
mechanisms for, 85
Chloro-oxirane
mutagenicity of, 75
Chlorpyriphos
delayed neurotoxicity due to, 421
Choline
altered hepatic foci and, 483
Chromaffin cells
catecholamine secretion from organophosphorus compounds and, 420-21
Chromosomal aberration tests
in vivo genetic toxicity and, 155
Cirrhosis
hepatoma and, 226

Clofibrate
altered hepatic foci and, 483
Clonidine
lymphocyte receptors for, 582-83
CNQX
N-methyl-D-aspartate and, 50
Cobalt
toxicity of
meso-dimercaptosuccinic acid and, 295
Colon cancer
alcohol consumption and, 219
beer consumption and, 221
Color additives
regulation of
pharmacokinetic data and, 203-17
regulatory safety requirements for, 202-3
Copper
toxicity of
meso-dimercaptosuccinic acid and, 295-96
Corticosteroids
arachidonic acid metabolism and, 6-7
Cortisone
circulating prolactin and, 572
Coumophos
oral toxicity of, 424
Creatine kinase
cellular S-thiolation and, 620
Creosote oil
delayed neurotoxicity due to, 421
Cumene peroxide
oxidation of
prostaglandin H synthase peroxidase and, 9
Cyclamate
acceptable exposure levels to, 214-15
Cyclazocine
anticonvulsant effects of, 730
Cyclic AMP
arachidonic acid release from membranes and, 6
serotonin receptors and, 319-23
synthesis of, 138
2',3'-Cyclic nucleotide-3'-phosphohydrolase
organophosphorus-induced delayed neurotoxicity and, 430
Cyclohexylamine
adverse effects of, 215
Cyclooxygenase
copurification with prostaglandin H synthase, 2-3
Cyclooxygenase pathway
arachidonic acid and, 2
Cyclophosphamide
side effects of
meso-dimercaptosuccinic acid and, 300-1
Cyproterone acetate
altered hepatic foci and, 479
Cysteamine
galactosamine-induced hepatic necrosis and, 301
Cysteine-S-sulfate
sulfite oxidase deficiency and, 54
Cytochrome P-450
acetaminophen toxicity and, 181-82
alcohol and, 227
butylated hydroxyanisole and, 452
chloroethylenes metabolized by, 76
suicide inactivators of, 172
Cytochrome P-450 monooxygenases
metabolic activation of chemicals to reactive electrophiles and, 2
Cytokines
immunoregulatory
glucocorticoids and, 575-76
neurotransmitter release and, 585

D

D-AP5
long-term potentiation and, 65
Decalin
renal toxicity of, 354
Dementia
β-N-methylamino-L-alanine and, 53-54
Dementia pugilistica
endogenous excitotoxins and, 57
Denaturing gradient gel electrophoresis, 379-80
Depression
bereavement and, 563
Desipramine
DSP-4 and, 388
Dextromethorphan
anticonvulsant effects of, 731-32
N-methyl-D-aspartate and, 50
Diabetes
experimental
G proteins and, 694
Diabetes insipidus
vasopressin agonists and, 513
Diallyl phthalate
forestomach tumors and, 447
Diamide
oxidative stress caused by, 174
Dianisidine
binding to macromolecules, 18
Diazepam
organophosphorus poisoning and, 428
1,2-Dibromo-3-chloropropane
bone marrow micronucleus tests and, 157
1,4-Dichlorobenzene
renal toxicity of, 354
cis-Dichlorodiammine platinum II
dose-related toxicity of, 297-98
p,p'-Dichlorodiphenyltrichloroethane
hepatocarcinogenesis and, 473
Dieldrin
altered hepatic foci and, 479
Dietary deficiency
See Nutritional deficiency
Dietary fat
carcinogenesis and, 230
Diethylnitrosamine
in alcoholic beverages, 220
Diethylstilbestrol
carcinogenicity of, 24-25
Digitonin
opioid receptor solubilization and, 126-27
Diglyceride lipase
arachidonic acid release from platelet membranes and, 6
Dihydroergotamine
serotonin receptor and, 311
7,8-Dihydroxy-7,8-dihydroBP
epoxidation of, 11-12
Diisopropylfluorophosphate
tissue plasminogen activator and, 96
Diltiazem
morphine analgesia and, 141
2,3-Dimercapto-1-propanesulfonic acid
lead toxicity and, 280
Dimethadione
teratogenicity of, 27
2,6-Dimethylacetaminophen
chemical reactivity and toxicity of, 183
3,5-Dimethylacetaminophen
chemical reactivity and toxicity of, 183
7,12-Dimethylbenzanthracene
mitochondrial glutathione and, 606

1,2-Dimethylhydrazine
bone marrow micronucleus tests and, 157
tumor induction by alcohol and, 224
Dimethylnitrosamine
in alcoholic beverages, 220
Dimethyl sulphate
cytotoxicity of, 174
Dioxin
acceptable exposure levels to, 215-17
action of, 251-69
genetic aspects of, 253-55
molecular aspects of, 256-68
4-Diphenylacetoxy-N-methylpiperidine methiodide
muscarinic receptors and, 634
Diphenylisobenzofuran
hydroperoxide-dependent oxidation of, 10
Diphtheria antitoxin
modern pharmaceutical industry and, 755-56
Diquat
cell injury caused by, 180
Dithiothreitol
S-nitroso derivatives of, 540
Divalent cations
phencyclidine binding and, 724-25
DNA
amplification of
polymerase chain reaction and, 380-81
recombinant
chimeric proteins and, 109
tissue plasminogen activator domain deletions and, 99
replicating
alcohol and, 225
DNA-alkylation repair
alcohol consumption and, 231-32
Domoate
poisoning due to, 54
Dopamine
lymphocyte receptors for, 582-83
phencyclidine and, 711-13
Dopamine-beta-hydroxylase
presynaptic integrity and, 396
Dopamine receptor
adenylate cyclase activity and, 138-39
DPAT
hypothermia and, 328
serotonin receptor and, 311
Drugs
approval of
basis for, 198
pharmacokinetics in, 198-202
hypersensitivity to
hapten hypothesis of, 176
DSP-4, 387-401
mechanism of action of, 388-400
neurotoxicity of, 395-96

E

Electrophiles
detoxification of
alcohol and, 230-31
reactive
metabolic activation of chemicals to, 2
Ellipticine
cytotoxicity of, 28
Endocrine system
interactions with immune system, 570-76
Endoplasmic reticulum
prostaglandin H synthase in, 3
Endorphin
immune responses and, 573-74
β-Endorphin
adenylate cyclase activity and, 139
tolerance to
oxytocin and, 521
Endothelial cells
PAI-1 in, 97
Endothelium-derived relaxing factor
composition of, 550-52
nitric oxide as, 543-44
vascular smooth muscle and, 536
Enkephalin
adenylate cyclase activity and, 139
immune responses and, 573-74
tolerance to
oxytocin and, 521
Enzyme code
serotonin receptor and, 336-38
Epidermal growth factor
de novo synthesis of prostaglandin H synthase and, 7
Epidermal growth factor receptor
protein kinase C and, 161
Epilepsy
endogenous excitotoxins and, 55-56
Esophageal cancer
alcohol consumption/tobacco use and, 221
Estrogen
circulating prolactin and, 572
α-globulin synthesis and, 352
Ethanol
See Alcohol
Ethyl acrylate
forestomach tumors induced by, 456-57
Ethylene dibromide
forestomach tumors and, 447
forestomach tumors induced by, 458
Ethylenes
chlorinated
carcinogenicity of, 73-88
Etoxadrol
anticonvulsant effects of, 730
Eugenol
peroxidase-dependent oxidation of, 14
toxicity of, 28
Excitotoxin receptors, 48-50
Excitotoxins
cell death due to, 50-51
central nervous system trauma and, 56-57
food, 52-54
metabolic disorders due to, 54-55
neurodegenerative disorders and, 52-61
neuropsychiatric disorders and, 47-66

F

Fatty acid β-oxidation pathway
3-ketoacyl-CoA thiolase and, 176
Fenthion
delayed neurotoxicity due to, 421
Fibrin
interaction of tissue plasminogen activator with, 111
Flunarizine
morphine analgesia and, 141
Food additives
regulation of
pharmacokinetic data and, 203-17
regulatory safety requirements for, 202-3
Food poisoning
domoate causing, 54
Forestomach
cell-proliferation studies using, 449-50
chemical carcinogens active in, 445-48

xenobiotic metabolism and, 448-49
Forestomach tumors
induced, 441-59
pathology of, 442-45
Furazolidine
reactive open chain acrylonitrile derivative of, 173
Fusel oils
in alcoholic beverages, 220

G

Gallamine
muscarinic receptors and, 634, 664-65
Gap junctions
carcinogenesis and, 161
Gasoline
unleaded
renal toxicity of, 354
Gastric cancer
chronic iron deficiency and, 234
Gastritis
alcohol abuse and, 226
Gel electrophoresis
denaturing gradient, 379-80
Genotoxicity
in vitro assays of, 150-54
in vivo assays of, 154-56
α-Globulin, 351-54
hydrolysis of, 355-57
metabolic fate of, 352-53
physiological functions of, 353
in vitro binding of, 357
α-Globulin nephropathy, 349-63
pathobiology of, 358-60
Glucocorticoids
circulating prolactin and, 572
α-globulin synthesis and, 352
immunosuppressive effects of, 574-76
Glucose-6-phosphate dehydrogenase
altered hepatic foci and, 469
Glucuronides
reactions with proteins, 179
Glutamate
membrane-depolarizing properties of, 48
neurodegenerative disorders and, 52-61
neuroendocrinopathies and, 52-53
neurotoxicity of, 47-48
amino acids mimicking, 49
Glutamate transmitter system
hypofunction of
schizophrenia and, 63
Glutamic dehydrogenase
amyotrophic lateral sclerosis and, 55
olivopontocerebellar degeneration and, 55
γ-Glutamyl transpeptidase
hepatomas and, 466
Glutathione, 603-24
conjugates of
cytotoxicity of, 172
mechanisms for formation of, 29-33
tetrachloroethylene metabolism and, 82-83
electrophile detoxification and, 230-31
lipid peroxidation and, 621-23
mitochondrial, 604-8
calcium and, 608-12
S-nitroso derivatives of, 540
Glutathione peroxidase
lipid peroxide levels and, 7
Glutathione reductase
1,3-bis(2-chloroethyl)-1-nitrosourea and, 174
Glyceraldehyde-3-phosphate dehydrogenase
altered hepatic foci and, 469
cellular S-thiolation and, 620
inactivation of
hydrogen peroxide and, 174
Glycine receptor
N-methyl-D-aspartate receptor and, 50, 721-24
Glycogen phosphorylase
cellular S-thiolation and, 620
Gold
excretion of
meso-dimercaptosuccinic acid and, 296
G proteins
activation and action of
mechanism of, 681-87
altered functions of, 693-95
hydrolysis of membrane phospholipids and, 688
muscarinic receptors and, 645-48
opioid receptors and, 137
PTX substrates of
molecular diversity of, 687-88
receptor interactions of, 692-93
serotonin receptors and, 318-19
signal transduction pathways mediated by, 675-81
Growth hormone
deficiencies of
immune system and, 571
Guanylate cyclase
activation of
nitric oxide and, 541

H

Halogenated aromatic hydrocarbons
compounds related to, 251-52
structures of, 252
Halogenated hydrocarbons
forestomach tumors and, 446
Halothane
hepatotoxicity of, 178-79
human antiendoplasmic reticulum antibodies and, 172
Head shaking response
serotonin and, 331-32
Hemangiosarcoma
liver
vinyl chloride-induced, 75
Hematin
prostaglandin H synthase and, 4
Hematopoiesis
chronic exposure to benzene and, 27
pyridoxine and, 236
Heme
prostaglandin H synthase and, 3-4
Hemoproteins
prostaglandin H synthase and, 4
Hepatic cells
proliferation of
chemically induced, 160-61
Hepatic necrosis
galactosamine-induced
meso-dimercaptosuccinic acid and, 301
Hepatitis
halothane, 178-79
Hepatitis B virus
hepatocellular carcinoma and, 233-34
Hepatocarcinogenesis
altered hepatic foci and, 465-88
multistage
stage of progression in, 485-87
multistage protocols for, 473-75
pyridoxine and, 236
Hepatocellular carcinoma
alcohol abuse and, 220
altered hepatic foci and, 485-87
hepatitis B virus and, 233-34
Hepatoma
cirrhosis and, 226

Heroin
tolerance to
oxytocin and, 521
3,3',4,4',5,5'-Hexachlorobiphenyl
structure of, 252
Hexachlorocyclohexane
altered hepatic foci and, 484
Hexahydrosiladifenidol
muscarinic receptors and, 634
n-Hexane
delayed neurotoxicants and, 423
neurotoxicity of, 175-76
2,5-Hexanedione
cytotoxicity of, 175-76
Himbacine
muscarinic receptors and, 634
Hormones
adenylate cyclase activity and, 139
anterior pituitary
immune system and, 570-74
arachidonic acid release from membranes and, 6
α-globulin synthesis and, 352
neurohypophyseal
central nervous system and, 516-22
steroid
circulating prolactin and, 572
Horseradish peroxidase
chemical oxidations catalyzed by, 8
Humoral immunity
pyridoxine and, 236
Huntington's disease
excitotoxins and, 59
Hydrazine
nitric oxide generation and, 537-38
Hydrogen peroxide
intracellular ATP levels and, 174
oxidation of
prostaglandin H synthase peroxidase and, 9
Hydroquinone
bone marrow effects of, 27
1-Hydroxy-3-aminopyrolid-2-one
N-Methyl-D-aspartate receptor and, 722
3'-Hydroxyacetanilide
acetaminophen toxicity and, 182-83
4-Hydroxyanisole
antineoplastic effects of, 453
9-Hydroxybenzo(a)pyrene
glutathione conjugate formation and, 33
Hydroxylamine
nitric oxide generation and, 537
4-Hydroxynonenal
cytotoxicity of, 180
5-Hydroxytryptamine
See Serotonin
Hypersensitivity
drug
hapten hypothesis of, 176
Hyperzincuria
alcohol abuse and, 234
Hypoglycemia
endogenous excitotoxins and, 56
pertussis vaccination and, 693
Hypothermia
DPAT causing, 328
Hypoxanthine-guaninephosphoribosyltransferase
mutagenicity testing and, 153

I

Ibotenic acid
Huntington's disease and, 59
Immune system
behavioral influences on, 562-70
cells of
neurotransmitter interactions with, 584-87
interactions with autonomic nervous system, 576-87
interactions with brain, 561-89
interactions with endocrine system, 570-76
opioids and, 137
stress and, 562-66
Immunogens
formation of, 176-79
Immunoglobulins
opioid-binding proteins and, 137
Immunosuppression
alcohol consumption and, 232-33
Indoleacetic acid
peroxidase-catalyzed oxidation of, 13
Indole alkaloids
protein kinase C and, 161
Indomethacin
butylated hydroxyanisole and, 453-54
Insecticides
delayed neurotoxicity due to, 421
Insulin
α-globulin synthesis and, 352
Interleukin-1
de novo synthesis of prostaglandin H synthase and, 7
production of
glucocorticoids and, 576
prolactin release and, 572
systemic release of growth hormone and, 571
Interleukin-2
de novo synthesis of prostaglandin H synthase and, 7
Interleukin-6 receptor
opioid-binding proteins and, 137
Ion channels
opioid receptors and, 140-42
Ipsapirone
serotonin receptor and, 311
Iron deficiency
alcohol abuse and, 234
Isophorone
renal toxicity of, 354

J

"Jake paralysis", 406
Jakob-Creutzfeldt syndrome
endogenous excitotoxins and, 61

K

Kainic acid
excitotoxin receptors sensitive to, 48
Huntington's disease and, 59
Kampo medicine, 758-59
Ketamine
anticonvulsant properties of, 729-32
seizure-related brain damage and, 56
Ketanserin
serotonin receptor and, 314, 331
Ketanserine
serotonin receptor and, 311
3-Ketoacyl-CoA thiolase
hepatotoxins binding to, 176
Kidney
cancer of
occupational exposure to petroleum products and, 360-61
tumors of
tetrachloroethylene-induced, 81-83
vinylidene chloride-induced, 77-78

Kynurenic acid
N-methyl-D-aspartate and, 50
N-Methyl-D-aspartate receptor and, 722-23

L

Lathyrus sativus
poisonous ingredient of, 53
Lead
exposure to
acceptable levels of, 213-14
developmental effects of, 279-80
poisoning with
meso-dimercaptosuccinic acid and, 286-89
Leptophos
delayed neurotoxicity due to, 421
Leukemia
tetrachloroethylene-induced, 84
Leukotrienes
conversion of arachidonic acid into, 2
d-Limonene
renal toxicity of, 354
Lipid hydroperoxides
prostaglandin biosynthesis and, 5
Lipid hyperperoxides
cytotoxicity of, 180
Lipid peroxides
oxidation of
prostaglandin H synthase peroxidase and, 9
Lipids
peroxidation of
alcohol and, 230
carbon tetrachloride inducing, 180
compounds causing, 180
glutathione and, 621-23
initiation of, 174-75
Lipotrope deficiency
alcohol abuse and, 235
15-Lipoxygenase
7,8-dihydroxy-7,8-dihydroBP epoxidation and, 12
Lipoxygenase pathway
arachidonic acid and, 2
Liver
angiosarcoma of
vinyl chloride-induced, 74-75
cancer of
aromatic amines and, 16
hemangiosarcoma of
vinyl chloride-induced, 75
tumors of
tri- and tetrachloroethylene-induced, 78-81
Long-term potentiation
N-methyl-D-aspartate receptor and, 64-65
Lung
tumors of
trichloroethylene-induced, 84
Lymphocytes
neurotransmitter receptors on, 581-83
Lymphoid organs
innervation of, 576-80

M

Macroglobulin
tissue plasminogen activator and, 97
Macrophages
glucocorticoids and, 575
Magnesium
phencyclidine binding and, 724-25
Malathion
delayed neurotoxicity due to, 423
Mammalian cells
chemically induced transformation of, 159-60
Manganese
excretion of
meso-dimercaptosuccinic acid and, 296-97
Manganese protoporphyrin IX
prostaglandin H synthase and, 4
McN-A-343
muscarinic receptors and, 634
Memory
N-methyl-D-aspartate receptors and, 64-65
Menadione
oxidative stress due to, 180
2-Mercaptoethylamine
S-nitroso derivatives of, 540
3-Mercaptopropionic acid
S-nitroso derivatives of, 540
Mercury
excretion of
meso-dimercaptosuccinic acid and, 297
poisoning with
meso-dimercaptosuccinic acid and, 289-90
Merphos
delayed neurotoxicity due to, 424
Meso-dimercaptosuccinic acid, 279-302
analytical determination of, 285-86
animal studies with, 292-300
biotransformation of, 291-92
developmental toxicity of, 299-300
extracellular distribution of, 281
human studies with, 286-92
pharmacokinetics of, 291
structure of, 281-85
Meso-dimercaptosuccinic acid mixed disulfide, 291-92
Mesulergine
serotonin receptor and, 311
Metabolic activation
cell injury and, 169
Metabolic cooperation assay
nongenotoxic carcinogens and, 161
Metabolic disorders
excitotoxic amino acids causing, 54-55
Metabolites
reactive
covalent interactions of, 170-73
interactions of, 170
Metal chelates
structure of, 281-85
Metallophorphyrins
prostaglandin H synthase and, 4
Metallothionein
cis-dichlorodiammine platinum II and, 298
Metergoline
serotonin receptor and, 311
Methamidophos
delayed neurotoxicity due to, 423
Methamidophos
delayed neurotoxicity due to, 421
Methamphetamine
dopaminergic nigrostriatal neurons and, 60
Methanol
delayed neurotoxicants and, 423
Methapyriline
hepatotoxicity of, 161
Methemoglobin
prostaglandin H synthase and, 4
Methimazole
prostaglandin H synthase peroxidase-dependent cooxidation reactions and, 6
Methiothepin
serotonin receptor and, 324
Methoctramine
muscarinic receptors and, 634
5-Methoxytryptamine
serotonin receptor and, 311

β-N-Methylamino-L-alanine
amyotrophic lateral sclerosis/parkinsonism/dementia complex due to, 53-54
N-Methyl-D-aspartate
excitotoxin receptors sensitive to, 48-50
N-Methyl-D-aspartate receptor
aging and, 65
developing central nervous system and, 61-64
features of, 50-51
memory and, 64-65
phencyclidine and, 715-27
3'-Methyl-4-dimethylaminoazobenzene
altered hepatic foci and, 466
Methylenecyclopropylacetic acid
hepatotoxicity of, 176
N-Methylformamide
hepatotoxicity of, 173
2-Methyl-5-hydroxytryptamine
serotonin receptor and, 332
3-Methylindole
peroxidase-catalyzed oxidation of, 13
toxicity of, 28
Methyl *iso*-butyl ketone
delayed neurotoxicants and, 423
N-Methyl-N-amylnitrosamine
tumor induction by, 223
N-Methyl-N-nitrosobenzylamine
forestomach epithelium and, 448-49
Methysergide
serotonin receptor and, 311, 324, 331
Metmyoglobin
prostaglandin H synthase and, 4
Mianserin
serotonin receptor and, 311
Micronuclei
chemically induced increases in
induced chromosomal damage and, 155
Microsomal cytochrome P-450-dependent biotransformation system
alcohol inducing, 227
Mipafox
delayed neurotoxicity due to, 421
Mitochondria
oxidative cell injury and, 615-17
Mitral valve prolapse
G proteins and, 694
MK-801
anticonvulsant effects of, 730-31
N-methyl-D-aspartate and, 50
memory formation and, 65
seizure-related brain damage and, 56
Wernicke/Korsakoff syndrome and, 61
Monobromobimane
meso-dimercaptosuccinic acid determinations and, 285
Monoclonal antibodies
fibrin-specific tissue plasminogen activator and, 112-13
Monocytes
cell-cell interactions of opioids modulating, 137
glucocorticoids and, 575
Monosodium glutamate
neuroendocrinopathies and, 52-53
Morphine
adenylate cyclase activity and, 139
analgesic effects of calcium-channel blocking agents and, 141
tolerance to oxytocin and, 521
Muscarinic receptors
adenylate cyclase activity and, 138-39
agonists of, 634
antagonists of, 633-34
genes for, 636-38
cloning of, 636-37
coexpression of, 638
expression in nervous system, 637
G-protein coupling and, 645-48
ligand binding and, 648-53
pharmacologic properties of, 660-65
regulation on cell surface, 653-55
signal transduction mechanisms of, 655-60
subtypes of, 633-66
agonist-binding properties of, 663-64
functions in nervous system, 659-60
primary sequence analysis of, 638-45
Mutagenesis testing
chemical development of, 150-53
Mutational spectra, 370-73
Mutational spectrometry, 369-83
Myocardial infarction
fibrinolytic response and, 91-92
PAI-1 and, 97

N

NAD(P) transhydrogenase
oxidizing agents and, 174
Naphthalene
binding of, 172
2-Naphthylamine
carcinogenicity of, 19
DNA adducts of, 20
oxidation of, 18
Necrobiosis
N-methyl-D-aspartate receptors and, 62
Nephropathy
α-globulin, 349-63
pathobiology of, 358-60
protein droplet biochemistry of, 354-58
Neuroendocrinopathies
glutamate and, 52-53
Neurofibrillary tangles
Alzheimer's disease and, 59-60
dementia pugilistica and, 57
Neurohypophyseal antagonists
central nervous system and, 522-23
Neurohypophyseal hormones
central nervous system and, 516-22
Neurohypophyseal peptides, 501-2
Neurolathyrism
β-N-oxalylamino-L-alanine and, 53
Neuropathy target esterase
organophosphorus-induced delayed neurotoxicity and, 429-30
Neuropeptides
enteric nervous system and, 580
thymic, 578
Neuropsychiatric disorders
excitotoxic amino acids and, 47-66
N-methyl-D-aspartate receptors and, 62-64
Neurotoxic esterase
inhibition of organophosphorus compounds and, 419-20
organophosphorus-induced delayed neurotoxicity and, 429-30
Neurotoxicity
delayed organophosphorus ester-induced, 405-35
Neurotransmission
criteria for, 580-84

Neurotransmitters
adenylate cyclase activity and, 139
interactions with cells of immune system, 584-87
Neurotrophism
N-methyl-D-aspartate receptors and, 61
Nicardipine
morphine analgesia and, 141
Nicotine
carcinogenic effect of tobacco and, 27-28
catecholamine secretion from chromaffin cells and, 420-21
Nifedipine
morphine analgesia and, 141
Nimodipine
morphine analgesia and, 141
Nitric oxide
chemistry of, 537-40
endothelium-derived, 535-55
biosynthesis of, 545-50
metabolism of, 544-45
as endothelium-derived relaxing factor, 543-44
pharmacology of, 540-43
5-Nitrofurans
bladder carcinogenicity of, 24
Nitroglycerin
vasodilator action of tissue thiols and, 535
Nitrosamides
forestomach tumors and, 446
Nitrosamines
in alcoholic beverages, 220
N-Nitrosomethylbenzylamine
tumor induction by, 223
N-Nitrosonornicotine
tumor induction by, 223
N-Nitrosopyrrolidine
tumor induction by, 223
S-Nitrosothiols
chemistry of, 540
pharmacology of, 540-43
Norepinephrine
immunomodulatory effects of, 583
phencyclidine and, 713-14
Nuclear membrane
prostaglandin H synthase in, 3
Nutritional deficiency
alcohol abuse and, 234-35
neuronal degeneration due to, 60-61

O

Olivopontocerebellar degeneration
glutamic dehydrogenase and, 55
Omethoate
delayed neurotoxicity due to, 421
Oncogenes
activation of, 1
OPIDN
See Organophosphorus ester-induced delayed neurotoxicity
Opioid-binding proteins
cloning of, 134-38
Opioid receptors, 123-42
molecular characterization of, 132-38
second messenger systems and, 138-52
solubilization, purification, and molecular weight analysis of, 125-32
Opioids
circulating prolactin and, 572
immune responses and, 573-74
immune system and, 137
pain control and, 759-60
tolerance to oxytocin and, 521
Organophosphorus compounds
age sensitivity to, 411
catecholamine secretion and, 420-21
chemical structure of, 406-9
clinical signs due to, 412-13
latent period of, 411-12
neuropathological changes due to, 413-18
neurotoxic esterase inhibition and, 419-20
phenylmethyl sulfonyl fluoride and, 418-19
poisoning with cholinergic effects of, 425
treatment of, 427-28
species selectivity of, 409-11
Organophosphorus ester-induced delayed neurotoxicity, 405-35
biochemical markers for, 428-30
compounds causing characteristics of, 406-21
in humans, 421-24
kinase-mediated protein phosphorylation and, 431-33
signs and symptoms of, 425-28
β-N-Oxalylamino-L-alanine
neurolathyrism due to, 53-54
Oxidative stress
cell injury and, 612-15
tissue injury due to, 173-75
α-tocopherol and, 620
Oxygen radicals
protein kinase C and, 161
Oxyhemoglobin
prostaglandin H synthase and, 4
Oxytocin, 501-24
agonists, 503-7
biological activity of, 506
analogs
antagonist activities of, 509
antagonists, 507-9
conformation-activity relationships of, 503-9
morphine tolerance and, 521

P

PAI-1
tissue plasminogen activator and, 97
Pain
control of opioids and, 759-60
Pancreatic cancer
alcohol consumption and, 219
Paraoxon
acetylcholinesterase activity and, 171
catecholamine secretion from chromaffin cells and, 420-21
Paraquat
cell injury caused by, 180
1-electron reduction of lipid peroxidation and, 180
Parathion
delayed neurotoxicity due to, 421, 423
Parkinsonism
excitotoxins and, 60
β-N-methylamino-L-alanine and, 53-54
Penicillamine
galactosamine-induced hepatic necrosis and, 301
S-nitroso derivatives of, 540
D-Penicillamine
arsenic poisoning and, 294
Pentazocine
proconvulsant effects of, 730
4-Pentenoic acid
hepatotoxicity of, 176
Peptides
lymphocyte receptors for, 582
neurohypophyseal, 501-2
Peroxidase
copurification with prostaglandin H synthase, 2-3

Peroxidases
classical reaction catalyzed by, 8
glutathione-dependent, 621-23
Peroxides
oxidation of prostaglandin H synthase peroxidase and, 9
Pertussis
G proteins and, 693
Petroleum products
occupational exposure to kidney cancer and, 360-61
Phalloidin
cellular effects of, 170
Pharmaceutical industry, 751-58
Pharmacokinetic models
physiologically based, 211-13
Pharmacokinetics
safety evaluation and regulation of drugs and, 197-217
Phencyclidine
anticonvulsant properties of, 729-32
behavior induced by, 727-29
memory formation and, 65
N-methyl-D-aspartate receptor-ionophore complex and, 715-27
monoaminergic/cholinergic transmitter systems and, 711-15
neuropharmacology of, 707-36
neuroprotective properties of, 732-34
seizure-related brain damage and, 56
Phencyclidine receptor
evidence for, 709-11
N-methyl-D-aspartate receptor and, 50, 63
Phenobarbital
altered hepatic foci and, 479, 483
Phenol
prostaglandin H synthase and, 4
Phenolic compounds
inhibitory potency of glutathione peroxidase and, 7
prostaglandin H synthase peroxidase and, 13
Phenylbutazone
peroxidase-catalyzed oxidation of, 12-13
Phenylbutazone peroxide
oxidation of prostaglandin H synthase peroxidase and, 9-10
Phenylmethyl sulfonyl fluoride
organophosphorus-induced delayed neurotoxicity and, 418-19
5-Phenyl-4-pentenylhydroperoxide
reaction of prostaglandin H synthase with, 8
Phenytoin
teratogenicity of, 26-27
Phe-Pro-Arg-chloromethylketone
tissue plasminogen activator and, 96-97
Phorbol esters
de novo synthesis of prostaglandin H synthase and, 7
tumor-promoting protein kinase C and, 161
Phosphoinositides
hydrolysis of serotonin receptors and, 324-27
Phospholipase C
arachidonic acid release from platelet membranes and, 6
Phospholipids
membrane G proteins and, 688
Pindolol
serotonin receptor and, 311
cis-2,3-Piperidine dicarboxylate
N-methyl-D-aspartate and, 50
Pirenzepine
muscarinic receptors and, 634
Pituitary growth hormone
α-globulin synthesis and, 352
Pituitary hormones
anterior immune system and, 570-74
Plasma
PAI-1 in, 97
Plasma membrane
prostaglandin H synthase in, 3
Plasminogen
one-chain tissue plasminogen activator and, 96
Platelet-derived growth factor
de novo synthesis of prostaglandin H synthase and, 7
Platelets
aggregation of nitric oxide and, 535
arachidonic acid release from, 6
function of serotonin and, 331
PAI-1 in, 97
Platinum
excretion of *meso*-dimercaptosuccinic acid and, 297-98
Plummer-Vinson syndrome
chronic iron deficiency and, 234
riboflavin deficiency and, 234
Polonium-210
excretion of *meso*-dimercaptosuccinic acid and, 298
Polyacetates
protein kinase C and, 161
Polyamines
phencyclidine binding and, 725-27
Polycyclic aromatic hydrocarbons
in alcoholic beverages, 220
carcinogenicity of, 21-23, 222
forestomach tumors and, 446
hydroperoxide-dependent oxidation of, 10
mitochondrial glutathione and, 606
Polymerase chain reaction
DNA amplification by, 380-81
Pralidoxime
organophosphorus poisoning and, 428
Prolactin
immunological processes and, 571-73
Propionic acid
forestomach tumors and, 447, 457-58
Propranolol
serotonin receptor and, 311
Prostacyclin
conversion of arachidonic acid into, 2
Prostaglandin H synthase
biochemistry of, 2-7
catalytic properties of, 5-6
chemical reactions initiated by, 12-15
hydroperoxide-derived oxidation and, 10-12
mechanism of cooxidation of, 7-12
peroxidase-derived oxidation and, 7-10
physical/chemical characteristics of, 3-5
regulation of, 6-7
sulfer-centered radicals formed by, 29-33
tissue and subcellular localization of, 3

Prostaglandin H synthase peroxidase
aromatic amine metabolism and, 16-18
formation of electrophiles by, 18-19
Prostaglandins
biosynthesis of
lipid hydroperoxides and, 5
conversion of arachidonic acid into, 2
Prostaglandin synthetase
butylated hydroxyanisole and, 453
Protein droplet nephropathy
biochemistry of, 354-58
Protein kinase C
activation of
carcinogenesis and, 161
Protein phosphorylation
kinase-mediated
organophosphorus-induced delayed neurotoxicity and, 431-33
Proteins
opioid-binding
cloning of, 134-38
S-thiolation in cells, 620-21
Protein synthesis
α-aminitin and, 170
Protein thiols
cell injury and, 617
maintenance of
α-tocopherol and, 617-20
Pseudocholinesterase
organophosphorus-induced delayed neurotoxicity and, 429
Pseudohypoparathyroidism
G proteins and, 693-94
Psychosis
phencyclidine and, 708
Psychotropic agents
immunomodulating effects of, 563
Putrescine
phencyclidine binding and, 725-26
Pyridoxine deficiency
alcohol abuse and, 234-35

Q

Quin-2
prostaglandin H synthase peroxidase and, 14
Quinolinic acid
Huntington's disease and, 59
Quinones
cytotoxicity of, 181
oxidative stress caused by, 174
Quinoxalinedione
N-methyl-D-aspartate and, 50
Quisqualic acid
excitotoxin receptors sensitive to, 48

R

Rauwolscine
serotonin receptor and, 311
Reactive metabolites
covalent interactions of, 170-73
interactions of, 170
Recombinant DNA technology
chimeric proteins and, 109
tissue plasminogen activator domain deletions and, 99
Rectal cancer
beer consumption and, 221
Retinal phosphodiesterase
G proteins and, 676
Retinoic acid
peroxidase-catalyzed oxidation of, 13
Retinol
metabolism of
alcohol consumption and, 229-30
Riboflavin deficiency
alcohol abuse and, 234
Rodents
carcinogenesis in
short-term tests and, 149-63

S

Safrole
altered hepatic foci and, 484
Salmonella
mutagenicity testing and, 151-52
Salmonella typhimurium/mammalian microsome assay, 152-53
Schizophrenia
glutamate transmitter system and, 63
Schizophreniform psychosis
phencyclidine and, 708
Second messengers
opioid receptors and, 138-42
Seizures
phencyclidine and, 729-32
Serotonin
depletion of
xylamine and, 397
phencyclidine and, 714-15
Serotonin receptors
adenylate cyclase activity and, 138-39, 318-19
ligand binding experiments with, 308-15
subtypes of, 307-38
classification and functions of, 327-38
molecular biological studies of, 315-18
second messenger linkages to, 318-27
Serotonin syndrome, 328
Signal transduction
G proteins and, 675-81
muscarinic receptors and, 655-60
Sister chromatid exchange
acetaldehyde and, 232
Skin cancer
riboflavin deficiency and, 234
Smooth muscle
vascular
endothelium-derived relaxing factor and, 536
Sodium ion channels
opioids and, 141-42
Sodium saccharin
forestomach tumors and, 447
Somatostatin
immune functions and, 584
lymphocyte receptors for, 582
Spectrometry
mutational, 369-83
Spermatogenesis
α-globulin and, 353
Spinal cord
injury to
endogenous excitotoxins and, 56-57
Spiperone
serotonin receptor and, 314, 324
Steroid hormones
circulating prolactin and, 572
Stomach cancer
alcohol consumption and, 219
beer consumption and, 221
Streptokinase
thrombolytic therapy with, 92
Stress
immune system and, 562-66
Substance K receptor
adenylate cyclase activity and, 138-39
Sulfite oxidase deficiency
excitotoxin-mediated, 54
Sulfur dioxide
cocarcinogenicity of, 25-26
Sulindac sulfide
oxidation of
prostaglandin H synthase peroxidase and, 9

Synapsin
phosphorylation of
serotonin receptors and, 323
Syrian hamster embryo cells
chemically induced
transformation of, 159-60

T

T-cell receptor
opioid-binding proteins and, 137
Telenzepine
muscarinic receptors and, 634
Temperature regulation
serotonin and, 328
Testosterone
α-globulin synthesis and, 352
3,3',4,4'-Tetrachlorobiphenyl
structure of, 252
2,3,7,8-Tetrachlorodibenzofuran
structure of, 252
2,3,7,8-Tetrachlorodibenzo-p-dioxin
action of, 251-69
genetic aspects of, 253-55
molecular aspects of, 256-68
structure of, 252
toxicity of, 216
Tetrachloroethylene
kidney tumors induced by, 81-83
leukemia induced by, 84
liver tumors induced by, 78-81
metabolism of, 79, 82
mutagenicity/carcinogenicity of, 76-83
12-0-Tetradecanoylphorbol-13-acetate
forestomach tumors and, 447
teratogenic effects of phenytoin and, 27
Tetramethylbenzidine
peroxidase-dependent oxidation of, 14
Thermoregulation
serotonin and, 328
Thiamine deficiency
neuronal degeneration due to, 60-61
Thioacetamide
reactive metabolites of
covalent interactions of, 172
Thiobarbiturates
N-methyl-D-aspartate and, 50
Thioglucose
S-nitroso derivatives of, 540
6-Thioguanine
mutagenicity testing and, 153
Thiol oxidation
oxidative stress and, 174
Thionitrites
See *S*-Nitrosothiols
Thrombolysis
initiation of
regulation of, 91-92
Thromboxane
conversion of arachidonic acid into, 2
Thymocytes
catecholamines and, 577-78
Thymus
neuropeptides in, 578
Thyroid cancer
beer consumption and, 221
Thyroid hormones
α-globulin synthesis and, 352
Tienilic acid
human antiendoplasmic reticulum antibodies and, 172
Tissue plasminogen activator, 91-115
functions of, 96
inhibition of, 96-97
oligosaccharide structures on, 95-96
second-generation research on, 97-98
structure of, 92-95
variants of, 98-115
Tobacco
carcinogenic effect of
nicotine and, 27-28
Tobacco smoke
carcinogens in, 222-23, 227
α-Tocopherol
oxidative stress and, 620
protein thiols and, 617-20
Trichloroacetic acid
peroxisome proliferation induced by, 79-81
Trichloroethylene
acro-osteolysis due to, 73-74
liver tumors induced by, 78-81
lung tumors induced by, 84
metabolism of, 79
mutagenicity/carcinogenicity of, 76-83
Trichloronate
delayed neurotoxicity due to, 421
Trichlorphon
delayed neurotoxicity due to, 421
Trifluoroacetylated protein disulfide isomerase, 172
Trimethadione
teratogenicity of, 26-27
2,2,4-Trimethylpentane
renal toxicity of, 354
Tri-*o*-cresyl phosphate
delayed neurotoxicity due to, 406, 421
Triphenyl phosphite
delayed neurotoxicity due to, 424
hydrolysis of, 408
Tumor necrosis factor
production of
glucocorticoids and, 576
Tumors
forestomach
induced, 441-59
kidney
tetrachloroethylene-induced, 81-83
vinylidene chloride-induced, 77-78
liver
tri- and tetrachloroethylene-induced, 78-81
lung
trichloroethylene-induced, 84
promotion of
carcinogenesis and, 158-59
Tyrosine hydroxylase
presynaptic integrity and, 396

V

Vanadium
excretion of
meso-dimercaptosuccinic acid and, 298
Vascular permeability
serotonin and, 331
Vasoactive intestinal peptide
circulating prolactin and, 572
immune functions and, 584
lymphocyte receptors for, 582
Vasopressin
amnesia and, 520-21
analogs
biological activities of, 513
biological multisubstituted, 514
antagonists
biological activities of, 517
avoidance behavior and, 518-20
conformation-activity relationships of, 509-15
receptor antagonists of, 515-16
Verapamil
morphine analgesia and, 141

Veratridine
catecholamine secretion from chromaffin cells and, 420-21
Vibrio cholerae infection
diarrhea due to
G proteins and, 693
Vinyl chloride
altered hepatic foci and, 476
carcinogenicity of, 74-76
metabolic activation of, 76
tumorigenic effect of alcohol and, 223
Vinyl chloride disease, 73
Vinylidene chloride
kidney tumors induced by, 77-78
mutagenicity/carcinogenicity of, 76-83
Vitamin A
metabolism of
alcohol consumption and, 229-30
Vitamin A deficiency
alcohol consumption and, 229-30
Vitamin B2 deficiency
alcohol abuse and, 234
Vitamin B6 deficiency
alcohol abuse and, 234-35
Vitamin E deficiency
alcohol abuse and, 235
prostacyclin formation in endothelial cells and, 7

W

Wernicke/Korsakoff syndrome
thiamine deficiency and, 60-61
Whooping cough
G proteins and, 693
Wilson's disease
meso-dimercaptosuccinic acid and, 295

X

Xenobiotics
metabolism of
chemical toxicity and, 1
forestomach epithelium and, 448-49
Xylamine, 387-401
mechanism of action of, 388-400
neurotoxicity of, 395-96

Y

Yeast
signal transduction system in, 691-92
Yohimbine
serotonin receptor and, 311

Z

Zinc deficiency
alcohol abuse and, 234